Sungyi.co.kr

1. Antibiotics 3. General API
2. Carbapenem
4. Under development
1-1. Cephalosporin Antibiotic 1-7. Anti-Cancer
1-2. Penicillins
1-8. Anti-Fungals
1-3. Anti-Bacterial 1-9. Anti-Ulcerants
1-4. CNS range 1-10. Anti-Diabetic
1-5. Cardiovasculars
1-11. Others
1-6. Anti-Retrovirals
* Intermediate
1-1. Cephalosporin Antibiotic
Document
Document
Veterinary
1-2. Penicillins
Document
Document
1-3. Anti-Bacterial
Document
Document
1-4. CNS range
Document
Document
Anti-Depressants
Anti-Convulsants
Hypnotics & Anti-Psychotics
1-5. Cardiovasculars
Document
Document
Anti-Hypertensives
Beta Blockers
Cholesterol Reducer
Anti-Thrombotic
Thiazide Diuretic
1-6. Anti-Retrovirals
Document
Document
1-7. Anti-Cancer
Document
Document
1-8. Anti-Fungals
Document
Document
1-9. Anti-Ulcerants
Document
Document
1-10. Anti-Diabetic
Document
Document
1-11. Others
Document
Document
Macrolide
Quinolones
Dermatological
Anti Histamine
Anticonvulsants
Nootropics&Neurotonics
Intermediate
Intermediate
Cefalosporin
7-Amino-3-Chloro Cephalosporanic Acid (7-ACCA) 7-Amino-3-Vinyl-3-Cepham 4-Carboxylic Acid (7-AVNA) 7-Amino-3-Nor Cephalosporanic Acid (7-ANCA) 7-Amino-3-Methoxy Methyl Cephalosporanic Acid(7-AMMCA) 7-Amino-3-Desacetoxy Cephalosporanic Acid (7-ADCA) (6R,7R)-7-Amino-8 oxo-3-(1-propenyl)-5-thia-1-azabicyclo(4.2.0)oct-2-e Cefuroxime Acid // Cefuroxime Axetil crystallin Contract manufacturing of Cefalosporin sodium sterile Lyophilization for Cfazolin,Cefoperazone, Cefmetazole, Cefotetan, Cefazedone.
Penicillin
Contract manufacturing of sodium sterile Lyophilization for Amoxycillin, Anti-Fungals
2,4-Dihydro-4[4- [4-(hydroyphenyl)-1-piperazinyl ]phenyl ]-2-(1-methylpr CIS-[2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazole-1-yl-methyl)1,3-dioxolan

Source: http://www.sungyi.co.kr/kor/images/s22.pdf

Microsoft word - it ahq on access to public administration employment_wider

Ad-Hoc Query on the access to public administration employment for citizens of other EU Member States Requested by IT EMN NCP on 25 May 2012 Reply requested by 18 June 2012 Responses requested from Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, P

micromri.com

The Journal of Clinical Endocrinology & Metabolism 92(4):1305–1310Copyright © 2007 by The Endocrine Society The Peroxisome Proliferator-Activated Receptor- ␥ Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial Andrew Grey, Mark Bolland, Greg Gamble, Diana Wattie, Anne Horne, James Davidson, and Ian R.

Copyright © 2018 Medical Abstracts